title: First clinical experience with a new TCR/CD3-monoclonal antibody (BMA 031) in kidney transplant patients.
authors.forename: W
authors.initials: W
authors.lastname: Land
authors.forename: G
authors.initials: G
authors.lastname: Hillebrand
authors.forename: W D
authors.initials: WD
authors.lastname: Illner
authors.forename: D
authors.initials: D
authors.lastname: Abendroth
authors.forename: E
authors.initials: E
authors.lastname: Hancke
authors.forename: S
authors.initials: S
authors.lastname: Schleibner
authors.forename: C
authors.initials: C
authors.lastname: Hammer
authors.forename: J
authors.initials: J
authors.lastname: Racenberg
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000945:Antigens, Differentiation, T-Lymphocyte; D001379:Azathioprine / Q000627:therapeutic use; D017252:CD3 Complex; D002452:Cell Count; D003524:Cyclosporins / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007668:Kidney / Q000187:drug effects; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000378:metabolism; D008775:Methylprednisolone / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell
chemical_list: D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D003524:Cyclosporins; D011948:Receptors, Antigen, T-Cell; D001379:Azathioprine; D008775:Methylprednisolone